Ipilimumab (Yervoy) for Mesothelioma

Ipilimumab, marketed as Yervoy, is a CTLA-4 immune checkpoint inhibitor approved by the FDA in combination with nivolumab (Opdivo) for the first-line treatment of unresectable malignant pleural mesothelioma. Originally approved for metastatic melanoma in 2011, ipilimumab became a foundational drug in the era of cancer immunotherapy. Its approval for mesothelioma in October 2020 provided patients with the first alternative to chemotherapy as initial treatment in over 16 years.¹

Ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an inhibitory receptor expressed on T cells. CTLA-4 functions as an early immune checkpoint — it competes with the co-stimulatory receptor CD28 for binding to B7 ligands on antigen-presenting cells, effectively dampening T cell activation at the priming stage. By blocking CTLA-4, ipilimumab removes this early brake on immune activation, allowing T cells to become fully activated against tumor antigens. This mechanism is complementary to nivolumab's PD-1 blockade, which removes a later checkpoint in the immune response.²

The rationale for combining ipilimumab with nivolumab — known as dual checkpoint blockade — is that the two drugs release immune brakes at different stages of the T cell response cycle. Ipilimumab enhances T cell activation and proliferation in lymph nodes, while nivolumab prevents T cell exhaustion at the tumor site. This combination produces a broader, more durable anti-tumor immune response than either agent alone, though it also increases the frequency and severity of immune-related adverse events.³

Ipilimumab carries a higher risk of immune-mediated toxicity than nivolumab, particularly gastrointestinal, hepatic, and endocrine adverse events. The CTLA-4 pathway plays a more fundamental role in maintaining immune tolerance to self-tissues, and blocking it produces more widespread autoimmune-like effects. Careful monitoring and early intervention with immunosuppressive therapy are essential components of safe ipilimumab administration.²

Ipilimumab is used exclusively in combination with nivolumab for mesothelioma, not as a single agent:¹

FDA-Approved Dosing Schedule

• Ipilimumab — 1 mg/kg (weight-based dosing) as a 30-minute intravenous infusion every 6 weeks
• Nivolumab — 360 mg (flat dose) as a 30-minute intravenous infusion every 3 weeks
• Treatment duration — Up to 2 years or until disease progression or unacceptable toxicity
• Pre-treatment labs — Complete blood count, comprehensive metabolic panel, thyroid function tests, and liver function tests before each cycle

CheckMate 743 Trial Data

The phase III trial that led to FDA approval enrolled 605 patients with untreated unresectable malignant pleural mesothelioma:¹

• Median overall survival — 18.1 months (nivolumab + ipilimumab) vs. 14.1 months (pemetrexed + cisplatin or carboplatin)
• 2-year overall survival — 41% vs. 27%
• Non-epithelioid histology — Median OS 18.1 vs. 8.8 months, representing a transformative improvement for sarcomatoid and biphasic subtypes
• Treatment-related adverse events (grade 3–4) — 30% in the immunotherapy arm vs. 32% in the chemotherapy arm
• Treatment discontinuation due to toxicity — 15% in the immunotherapy arm, primarily due to immune-related adverse events

Earlier Mesothelioma Studies

Prior to CheckMate 743, the MAPS2 trial (a phase II randomized study) evaluated nivolumab alone versus nivolumab plus ipilimumab in previously treated mesothelioma patients. The combination arm showed a higher disease control rate (50% vs. 44%) and prompted the design of the pivotal phase III study. The INITIATE trial also demonstrated promising activity of nivolumab/ipilimumab in the second-line setting.⁴

The addition of ipilimumab to nivolumab has changed the treatment landscape for mesothelioma, particularly for patients with non-epithelioid histology:¹

• Sarcomatoid mesothelioma — Previously associated with median survival under 8 months with chemotherapy, now achieving median survival over 18 months with dual checkpoint blockade
• Durable responses — A subset of patients achieves long-lasting responses that persist well beyond the 2-year treatment window, suggesting genuine immunological memory against the tumor
• Delayed response pattern — Unlike chemotherapy, immunotherapy responses may take longer to manifest and some patients may experience initial pseudoprogression (temporary tumor enlargement due to immune cell infiltration) before response
• Quality of life — Patients on immunotherapy generally report better quality of life than those on chemotherapy, with fewer systemic side effects and no cumulative toxicity

Ipilimumab carries a higher risk of immune-related adverse events than nivolumab alone, and patients should be vigilant about monitoring and reporting symptoms:²

• Immune-mediated colitis — The most common serious side effect of ipilimumab, occurring in 10–20% of patients receiving the combination. Symptoms include diarrhea (more than 4 stools per day above baseline), abdominal pain, cramping, and blood or mucus in stool. Mild cases are managed with anti-diarrheal medications; moderate to severe cases require treatment interruption and high-dose corticosteroids (prednisone 1–2 mg/kg daily)
• Hepatotoxicity — Elevated liver enzymes (AST/ALT) occur in 5–10% of patients and may indicate immune-mediated hepatitis. Usually detected on routine blood tests before symptoms develop. Severe cases require treatment discontinuation and corticosteroids
• Endocrinopathies — Ipilimumab can trigger autoimmune destruction of endocrine glands. Hypophysitis (pituitary inflammation) is particularly associated with ipilimumab and may cause headaches, fatigue, and hormonal deficiencies requiring lifelong hormone replacement. Thyroid dysfunction (hypothyroidism or hyperthyroidism) is also common and requires ongoing monitoring
• Skin toxicity — Rash, pruritus (itching), and rarely Stevens-Johnson syndrome or toxic epidermal necrolysis. Most skin reactions are mild (grade 1–2) and managed with topical corticosteroids and antihistamines
• Fatigue — Reported by 20–30% of patients. When persistent, it should be evaluated for underlying thyroid or adrenal dysfunction caused by immune-mediated endocrinopathy
• Rare but serious toxicities — Myocarditis (heart inflammation), nephritis (kidney inflammation), and neurological toxicities (Guillain-Barré syndrome, myasthenia gravis) are rare but potentially fatal. Any new cardiac, renal, or neurological symptoms require immediate medical evaluation

Patients should carry an immunotherapy wallet card at all times and ensure all healthcare providers — including dentists and emergency departments — are aware they are receiving checkpoint inhibitor therapy. Corticosteroids should not be started for irAE management without oncology guidance, as premature discontinuation can cause rebound flares.³